Event

Steven J. Pascoe

MBBSM MS
GSK

C. Elaine Jones

PhD
GSK

David Lomas

PhD, FRCP
University College London

Maggie Tabberer

MSc
GSK

Robert A. Wise

MD
Johns Hopkins Bayview;Johns Hopkins Medicine;Johns Hopkins Univ;Johns Hopkins University;Johns Hopkins University School of Medicine

Fernando J. Martinez

MD, MS
Cornell University;New York-Presbyterian Hospital/Weill Cornell Medical Center;Weill Cornell Medical College;Weill Cornell Medical College, Cornell University;Weill Cornell Medicine

Gerard J. Criner

MD
Lewis Katz School of Medicine at Temple University;Lewis Katz School of Medicine at Temple University, Temple University Hospital;Temple Univ Hosp;Temple Univ Hospital;Temple University;Temple Univers

Mark T. Dransfield

MD
Lung Health Center, University of Alabama at Birmingham;UAB;Univ of Alabama Birmingham;Univ of Alabama Birmingham & Birmingham VA Med Ctr;Univ of Alabama Birmingham & Birmingham VA Med Ctr;Un

David M. G. Halpin

PhD
Royal Devon and Exeter Hospital;Royal Devon and Exeter Hospital, University of Exeter Medical School

Jean Brooks

MSc
GSK

Noushin Brealey

MRCGP MSc
GSK

Sally Kilbride

MSc
GSK

Dave Singh

MD, NP
Manchester Academic Health Science Centre, The University of Manchester;Medicines Evaluation Unit (MEU), University of South Manchester NHS Foundation Trust;The University of Manchester, University Ho

Peter Lange

MD
University of Copenhagen

MeiLan King. Han

MD, MS
University of Michigan

Nicola C. Day

PhD
GSK

Frank Barnhart

D.V.M.
GSK

David A. Lipson

MD
GlaxoSmithKline;GSK;GSK and Perelman School of Medicine, University of Pennsylvania

Single Inhaler Triple-Therapy (ICS/LAMA/LABA) Versus Dual-Therapy (ICS/LABA or LAMA/LABA) in Patients with COPD at Risk of Exacerbations: Efficacy and Safety Results of the Phase III IMPACT Trial